Q BioMed (QBIO) 10-Q 15 Oct 19 2019 Q3 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	9 Months Ended
	Aug. 31, 2019	Oct. 14, 2019
Document and Entity Information
Entity Registrant Name	Q BIOMED INC.
Document Type	10-Q
Document Period End Date	Aug. 31, 2019
Entity Current Reporting Status	Yes
Amendment Flag	false
Entity Central Index Key	0001596062
Current Fiscal Year End Date	--11-30
Entity Common Stock, Shares Outstanding		16,720,871
Entity Filer Category	Non-accelerated Filer
Document Fiscal Year Focus	2019
Document Fiscal Period Focus	Q3
Entity Emerging Growth Company	false
Entity Small Business	true
Entity Shell Company	false

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($)	Aug. 31, 2019	Nov. 30, 2018
Current assets:
Cash	$ 301,673	$ 2,684,413
Prepaid expenses	28,546	12,500
Total current assets	330,219	2,696,913
Intangible assets, net	462,500	500,000
Total Assets	792,719	3,196,913
Current liabilities:
Accounts payable	751,402	172,628
Accrued expenses	1,302,527	219,602
Accrued expenses - related party	25,000	7,500
Accrued interest payable	101,626	29,639
Investor advances	193,250
Convertible note payable, net	485,000
Total current liabilities	2,858,805	429,369
Long-term liabilities:
Convertible notes payable, net	3,976,709	2,873,272
Total long term liabilities	3,976,709	2,873,272
Total Liabilities	6,835,514	3,302,641
Commitments and Contingencies (Note 6)
Stockholders' Deficit:
Preferred stock, $0.001 par value; 100,000,000 shares authorized; no shares issued and outstanding as of August 31, 2019 and November 30, 2018
Common stock, $0.001 par value; 250,000,000 shares authorized; 15,182,227 and 14,290,236 shares issued and outstanding as of August 31, 2019 and November 30, 2018, respectively	15,182	14,290
Additional paid-in capital	33,866,087	31,994,129
Accumulated deficit	(39,924,064)	(32,114,147)
Total Stockholders' Deficit	(6,042,795)	(105,728)
Total Liabilities and Stockholders' Deficit	$ 792,719	$ 3,196,913

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares	Aug. 31, 2019	Nov. 30, 2018
Condensed Consolidated Balance Sheets
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, shares authorized	100,000,000	100,000,000
Preferred stock, issued	0	0
Preferred stock, outstanding	0	0
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	250,000,000	250,000,000
Common stock, shares issued	15,182,227	14,290,236
Common stock, shares outstanding	15,182,227	14,290,236

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations - USD ($)	3 Months Ended		9 Months Ended
	Aug. 31, 2019	Aug. 31, 2018	Aug. 31, 2019	Aug. 31, 2018
Operating expenses:
General and administrative expenses	$ 968,383	$ 1,996,391	$ 3,406,853	$ 4,547,761
Research and development expenses	786,600	989,140	2,672,715	2,624,753
Total operating expenses	1,754,983	2,985,531	6,079,568	7,172,514
Other expenses:
Interest expense	476,627		1,137,271
Change in fair value of embedded derivatives	118,000		396,000
Loss on induced conversion of debt	197,078		197,078
Total other expenses	791,705		1,730,349
Net loss	$ (2,546,688)	$ (2,985,531)	$ (7,809,917)	$ (7,172,514)
Long-term Liabilities:
Net loss per share - basic and diluted	$ (0.17)	$ (0.21)	$ (0.54)	$ (0.53)
Weighted average shares outstanding, basic and diluted	14,756,302	14,019,683	14,580,630	13,579,917

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Changes in Shareholders' Equity - USD ($)	Common Stock	Additional Paid in Capital	Accumulated Deficit	Total
Beginning balance, Shares at Nov. 30, 2017	12,206,409
Beginning balance, Amount at Nov. 30, 2017	$ 12,206	$ 23,187,408	$ (22,843,370)	$ 356,244
Share based compensation for services, Amount	$ 159	1,953,158		1,953,317
Share based compensation for services, Shares	159,028
Issuance of common stock and warrants for cash, net of offering costs, Amount	$ 1,712	4,943,539		4,945,251
Issuance of common stock and warrants for cash, net of offering costs, Shares	1,711,875
Net loss			(7,172,514)	(7,172,514)
Ending balance, Shares at Aug. 31, 2018	14,077,312
Ending balance, Amount at Aug. 31, 2018	$ 14,077	30,084,105	(30,015,884)	82,298
Beginning balance, Shares at May. 31, 2018	13,987,130
Beginning balance, Amount at May. 31, 2018	$ 13,987	28,902,745	(27,030,353)	1,886,379
Share based compensation for services, Amount	$ 90	1,181,361		1,181,450
Share based compensation for services, Shares	90,182
Net loss			(2,985,531)	(2,985,531)
Ending balance, Shares at Aug. 31, 2018	14,077,312
Ending balance, Amount at Aug. 31, 2018	$ 14,077	30,084,105	(30,015,884)	82,298
Beginning balance, Shares at Nov. 30, 2018	14,290,236
Beginning balance, Amount at Nov. 30, 2018	$ 14,290	31,994,129	(32,114,147)	(105,728)
Share based compensation for services, Amount	$ 527	1,349,081		1,349,608
Share based compensation for services, Shares	526,541
Issuance of common stock to partially convert notes payable	$ 147	293,579		293,726
Issuance of common stock to partially convert notes payable (in shares)	146,863
Issuance of common stock as inducement to partially convert notes payable	$ 188	196,890		197,078
Issuance of common stock as inducement to partially convert notes payable	187,693
Issuance of common stock to defer monthly contingent payment of convertible note	$ 30	32,408		32,438
Issuance of common stock to defer monthly contingent payment of convertible note	30,894
Net loss			(7,809,917)	(7,809,917)
Ending balance, Shares at Aug. 31, 2019	15,182,227
Ending balance, Amount at Aug. 31, 2019	$ 15,182	33,866,087	(39,924,064)	(6,042,795)
Beginning balance, Shares at May. 31, 2019	14,677,136
Beginning balance, Amount at May. 31, 2019	$ 14,676	33,002,224	(37,377,376)	(4,360,476)
Share based compensation for services, Amount	$ 141	340,986		341,127
Share based compensation for services, Shares	139,641
Issuance of common stock to partially convert notes payable	$ 147	293,579		293,726
Issuance of common stock to partially convert notes payable (in shares)	146,863
Issuance of common stock as inducement to partially convert notes payable	$ 188	196,890		197,078
Issuance of common stock as inducement to partially convert notes payable	187,693
Issuance of common stock to defer monthly contingent payment of convertible note	$ 30	32,408		32,438
Issuance of common stock to defer monthly contingent payment of convertible note	30,894
Net loss			(2,546,688)	(2,546,688)
Ending balance, Shares at Aug. 31, 2019	15,182,227
Ending balance, Amount at Aug. 31, 2019	$ 15,182	$ 33,866,087	$ (39,924,064)	$ (6,042,795)

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Cash Flows - USD ($)	9 Months Ended
	Aug. 31, 2019	Aug. 31, 2018
Cash flows from operating activities:
Net loss	$ (7,809,917)	$ (7,172,514)
Adjustments to reconcile net loss to net cash used in operating activities
Share based compensation for services	1,349,608	1,953,317
Change in fair value of embedded conversion option	396,000
Accretion of debt discount	907,437
Amortization expense	37,500
Loss on induced conversion of debt	197,078
Non-cash interest expense	32,438
Changes in operating assets and liabilities:
Prepaid expenses	(16,046)
Accounts payable and accrued expenses	1,646,699	236,015
Accrued expenses - related party	17,500
Accrued interest payable	165,713
Net cash used in operating activities	(3,075,990)	(4,983,182)
Cash flows from financing activities:
Proceeds from investor advances	193,250
Proceeds received from issuance of short-term convertible note, net of original issuance discount and lender's fees	500,000
Proceeds received for issuance of common stock and warrants, net of offering costs		4,945,251
Net cash provided by financing activities	693,250	4,945,251
Net decrease in cash	(2,382,740)	(37,931)
Cash at beginning of period	2,684,413	824,783
Cash at end of period	301,673	786,852
Supplemental disclosures:
Cash paid for interest	31,524
Cash paid for income taxes
Non-cash financing activities:
Issuance of common stock to partially convert notes payable	293,726
Accrued debt issuance costs	$ 15,000

Organization of the Company and

Organization of the Company and Description of the Business	9 Months Ended
	Aug. 31, 2019
Organization of the Company and Description of the Business
Organization of the Company and Description of the Business	Note 1 - Organization of the Company and Description of the Business Q BioMed Inc. (“Q BioMed” or “the Company”), incorporated in the State of Nevada on November 22, 2013, is a biomedical acceleration and development company focused on licensing, acquiring and providing strategic resources to life sciences and healthcare companies. Q BioMed intends to mitigate risk by acquiring multiple assets over time and across a broad spectrum of healthcare related products, companies and sectors. The Company intends to develop these assets to provide returns via organic growth, revenue production, out-licensing, sale or spinoff new public companies. On December 7, 2016, the Company formed its wholly-owned subsidiary in Cayman Islands, “Q BioMed Cayman SEZC” (the “Subsidiary”). The accompanying condensed consolidated financial statements include the accounts of the Company’s wholly-owned subsidiary. All intercompany balances and transactions have been eliminated in consolidation.

Basis of Presentation

Basis of Presentation	9 Months Ended
	Aug. 31, 2019
Basis of Presentation
Basis of Presentation	Note 2 - Basis of Presentation The accompanying interim period unaudited condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America (“U.S. GAAP”) and applicable rules and regulations of the Securities and Exchange Commission ("SEC") regarding interim financial reporting. These condensed consolidated financial statements are unaudited and should be read in conjunction with the audited consolidated financial statements included in the Company's Annual Report on Form 10-K for the year ended November 30, 2018. Certain disclosures included in the annual financial statements have been condensed or omitted from these financial statements as they are not required for interim financial statements under U.S. GAAP and the rules of the SEC. These unaudited consolidated financial statements reflect all adjustments that are, in the opinion of management, necessary for a fair statement of the results for the interim periods presented. These adjustments are of a normal, recurring nature. Interim period operating results may not be indicative of the operating results for a full year. The Company currently operates in one business segment focusing on licensing, acquiring and providing strategic resources to life sciences and healthcare companies. The Company is not organized by market and is managed and operated as one business. A single management team reports to the chief operating decision maker, the Chief Executive Officer, who comprehensively manages the entire business. The Company does not currently operate any separate lines of business. Going Concern The accompanying condensed consolidated financial statements are prepared assuming the Company will continue as a going concern, which contemplates the realization of assets and liquidation of liabilities in the normal course of business. The Company has and is expected to incur net losses and cash outflows from operations in pursuit of extracting value from its acquired intellectual property. These matters, amongst others, raise doubt about the Company’s ability to continue as a going concern. The Company has not generated any revenue from operations since inception and has limited assets upon which to commence its business operations. Management anticipates that the Company will have to raise additional funds and/or generate revenue from drug sales within twelve months to continue operations. Additional funding will be needed to implement the Company’s business plan that includes various expenses such as fulfilling our obligations under licensing agreements, legal, operational set-up, general and administrative, marketing, employee salaries and other related start-up expenses. Obtaining additional funding will be subject to a number of factors, including general market conditions, investor acceptance of our business plan and initial results from our business operations. These factors may impact the timing, amount, terms or conditions of additional financing available to us. If the Company is unable to raise sufficient funds, management we will be forced to scale back the Company’s operations or cease our operations. Management has determined that there is substantial doubt about the Company’s ability to continue as a going concern within one year after the condensed consolidated financial statements are issued. The accompanying condensed consolidated financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts, or amounts and classification of liabilities that might result from this uncertainty.

Summary of Significant Accounti

Summary of Significant Accounting Policies	9 Months Ended
	Aug. 31, 2019
Summary of Significant Accounting Policies
Summary of Significant Accounting Policies	Note 3 - Summary of Significant Accounting Policies The Company’s significant accounting policies are disclosed in the audited financial statements for the year ended November 30, 2018 included in the Company’s Form 10-K. Since the date of such financial statements, there have been no changes to the Company’s significant accounting policies. Recent accounting pronouncements On February 2016, the FASB issued ASU No. 2016‑02, Leases (Topic 842) . Under the new guidance, lessees will be required to recognize all leases (with the exception of short-term leases) on the balance sheet as a lease liability, which is a lessee’s obligation to make lease payments arising from a lease, measured on a discounted basis and a right-of-use asset, which is an asset that represents the lessee¹s right to use, or control the use of, a specified asset for the lease term. The guidance in ASU 2017‑11 is effective for the Company on December 1, 2019. Early adoption is permitted, and the guidance is to be applied using a full or modified retrospective approach. The Company is currently evaluating the impact of the new standard on its condensed consolidated financial statements. In July 2017, the FASB issued ASU 2017‑11, Earnings Per Share (Topic 260); Distinguishing Liabilities from Equity (Topic 480); Derivatives and Hedging (Topic 815): (Part I) Accounting for Certain Financial Instruments with Down Round Features, (Part II) Replacement of the Indefinite Deferral for Mandatorily Redeemable Financial Instruments of Certain Nonpublic Entities and Certain Mandatorily Redeemable Noncontrolling Interests with a Scope Exception. The ASU allows companies to exclude a down round feature when determining whether a financial instrument (or embedded conversion feature) is considered indexed to the entity’s own stock. As a result, financial instruments (or embedded conversion features) with down round features may no longer be required to be accounted classified as liabilities. A company will recognize the value of a down round feature only when it is triggered and the strike price has been adjusted downward. For equity-classified freestanding financial instruments, such as warrants, an entity will treat the value of the effect of the down round, when triggered, as a dividend and a reduction of income available to common shareholders in computing basic earnings per share. For convertible instruments with embedded conversion features containing down round provisions, entities will recognize the value of the down round as a beneficial conversion discount to be amortized to earnings. The guidance in ASU 2017‑11 is effective for the Company on December 1, 2019. Early adoption is permitted, and the guidance is to be applied using a full or modified retrospective approach. The Company is currently evaluating the impact of the new standard on its condensed consolidated financial statements. Recent adopted pronouncements In May 2014, the FASB issued ASU 2014‑09, Revenue from Contracts with Customers (Topic 606), as modified by ASU 2015‑14, Revenue from Contracts with Customers (Topic 606): Deferral of the Effective Date , ASU 2016‑08, Revenue from Contracts with Customers (Topic 606): Principal versus Agent Considerations (Reporting Revenue Gross versus Net), ASU 2016‑10, Revenue from Contracts with Customers (Topic 606): Identifying Performance Obligations and Licensing , and ASU 2016‑12, Revenue from Contracts with Customers (Topic 606): Narrow-Scope Improvements and Practical Expedients . The revenue recognition principle in ASU 2014‑09 is that an entity should recognize revenue to depict the transfer of goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. In addition, new and enhanced disclosures will be required. Companies may adopt the new standard either using the full retrospective approach, a modified retrospective approach with practical expedients, or a cumulative effect upon adoption approach. The adoption of this standard on December 1, 2018 did not impact the Company’s condensed consolidated financial statements. In August 2016, the FASB issued ASU No. 2016‑15, Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments . This new standard clarifies certain aspects of the statement of cash flows, including the classification of debt prepayment or debt extinguishment costs or other debt instruments with coupon interest rates that are insignificant in relation to the effective interest rate of the borrowing, contingent consideration payments made after a business combination, proceeds from the settlement of insurance claims, proceeds from the settlement of corporate-owned life insurance policies, distributions received from equity method investees and beneficial interests in securitization transactions. This new standard also clarifies that an entity should determine each separately identifiable source of use within the cash receipts and payments on the basis of the nature of the underlying cash flows. In situations in which cash receipts and payments have aspects of more than one class of cash flows and cannot be separated by source or use, the appropriate classification should depend on the activity that is likely to be the predominant source or use of cash flows for the item. The adoption of this standard on December 1, 2018 did not impact the Company’s condensed consolidated financial statements. In June 2018, the FASB issued ASU 2018‑07, Compensation - Stock Compensation (Topic 718), Improvements to Nonemployee Share-Based Payment Accounting . This ASU is intended to simplify aspects of share-based compensation issued to non-employees by making the guidance consistent with the accounting for employee share-based compensation. The adoption of this standard on December 1, 2018 did not impact the Company’s condensed consolidated financial statements.

Loss per share

Loss per share	9 Months Ended
	Aug. 31, 2019
Loss per share
Loss per share	Note 4 - Loss per share Basic net loss per share was calculated by dividing net loss by the weighted-average common shares outstanding during the period. Diluted net loss per share was calculated by dividing net loss by the weighted-average common shares outstanding during the period using the treasury stock method or the two-class method, whichever is more dilutive. The table below summarizes potentially dilutive securities that were not considered in the computation of diluted net loss per share because they would be anti-dilutive. August 31, Potentially dilutive securities 2019 2018 Warrants 4,984,000 4,955,058 Convertible Notes 2,171,000 — Stock Options 1,200,000 900,000

Convertible Notes

Convertible Notes	9 Months Ended
	Aug. 31, 2019
Convertible Notes.
Convertible Notes	Note 5 - Convertible Notes August 31, 2019 November 30, 2018 Convertible Notes Payable, current: Principal value of 2019 Debenture $ 550,000 $ — Debt discount (65,000) — Carrying value of 2019 Debenture 485,000 — Total carrying value of convertible notes payable, current $ 485,000 $ — Convertible Notes Payable, long-term: Principal value of 2018 Debenture $ 3,800,000 $ 4,000,000.00 Fair value of bifurcated contingent put option 658,000 262,000 Debt discount (481,291) (1,388,728) Carrying value of 2018 Debenture 3,976,709 2,873,272 Total carrying value of convertible notes, long-term $ 3,976,709 $ 2,873,272 2019 Debenture On August 28, 2019, the Company entered into a securities purchase agreement with an accredited investor pursuant to which the Company sold a convertible debenture (the “2019 Debenture”) with a maturity date of twelve months after the issuance thereof for $500,000. The 2019 Debenture is in the aggregate principal amount of $550,000, which amount includes an original issue discount of $40,000 and payment of the lender’s legal fees of $10,000. The 2019 Debenture carries an interest rate of 10% per annum. Upon an event of default, as defined, the outstanding balance of the 2019 Debenture bears interest at a rate of 18% per annum. The Company may prepay the 2019 Debenture at 110% of the outstanding aggregate principal amount within the first six months of issuance and at 125% of the outstanding aggregate principal amount thereafter. In certain circumstances, a premium is due upon the outstanding balance upon written notice from the lender. A premium of fifteen percent is due for each occurrence of any major default, a premium of ten percent is due for each occurrence of an unapproved variable security issuance default, and a premium of five percent is due for each occurrence of any minor default. The lender has the right to convert the outstanding aggregate principal amount at any time at the conversion price of $2.50 per share. At any time that is six months after the issuance, the lender may redeem a portion of the 2019 Debenture, not to exceed $150,000 in any month. The Company may pay such a redemption in cash and/or shares of its common stock. Any payment of such a redemption in shares of common stock shall be made at the lesser of $2.50 or 93% of the average of the four lowest VWAPs in the prior ten trading day, provided that no such conversion price shall be less than $2.00. Any payment of such a redemption in cash shall be at 120% of the amount being redeemed. Moreover, the Company has the right to defer up to two (2) separate redemptions for up to thirty (30) days each by providing written notice to the lender within three (3) trading days of its receipt of a redemption notice. In the event the Company elects to exercise its deferral right, the 2019 Debenture’s outstanding balance shall automatically be increased by ten percent (10%) of the redemption amount to which such deferral relates. 2018 Debentures The monthly payment provision within the 2018 Debentures is a contingent put option that is required to be separately measured at fair value, with subsequent changes in fair value recognized in the Condensed Consolidated Statement of Operations. The fair value estimate is a Level 3 measurement. The Company estimated the fair value of the monthly payment provision by estimating the probability of the occurrence of a Triggering Date and applying the probability to the discounted maximum redemption premium for any given payment with the following key inputs: August 31, 2019 November 30, 2018 Stock price $0.91 $1.95 - $2.97 Terms (years) 0.50-0.66 1.2 - 1.4 Volatility 79.78% 72.1% - 76.5% Risk-free rate 1.89% - 2.10% 2.4% - 2.5% Dividend yield 0.00% 0.00% Discount rate 35.17% 35.17% In August 2019, the Company modified the conversion price for $293,726 of principal and accrued interest outstanding under the 2018 Debentures and holders immediately converted the amount into 334,556 shares of the Company’s common stock. Had the holders converted $293,726 of principal and accrued interest under the previously existing conversion terms, the holders would have received 146,863 shares of the Company's common stock. The additional 187,693 shares received upon conversion, with an aggregate fair value of $197,078, is recognized in the accompanying Condensed Consolidated Statements of Operations as a loss on induced conversion of debt. Interest expense Interest expense, included in the accompanying Condensed Consolidated Statements of Operations, is comprised of the following for each period presented: For the three months ended August 31, For the nine months ended August 31, 2019 2018 2019 2018 Interest expense based on the coupon interest rate of the outstanding debt $ 55,000 $ — $ 166,000 $ — Accretion of debt discount $ 389,000 $ — $ 907,000 $ — Costs incurred to defer monthly contingent payments of convertible notes $ 32,000 $ — $ 64,000 $ —

Commitments and Contingencies

Commitments and Contingencies	9 Months Ended
	Aug. 31, 2019
Commitments and Contingencies
Commitments and Contingencies	Note 6 - Commitments and Contingencies Legal Periodically, the Company reviews the status of significant matters, if any exist, and assesses our potential financial exposure. If the potential loss from any claim or legal claim is considered probable and the amount can be estimated, the Company accrues a liability for the estimated loss. Legal proceedings are subject to uncertainties, and the outcomes are difficult to predict. Because of such uncertainties, accruals are based on the best information available at the time. As additional information becomes available, the Company reassesses the potential liability related to pending claims and litigation. BNI matter On December 28, 2018, the Company commenced litigation against BioNucleonics, Inc. (“BNI”) and parties related to BNI in the Supreme Court of New York, New York County (removed to federal court in February 2019). The litigation stems from a license agreement that the Company entered into with BNI in 2016 and amended from time to time. Under the agreement with BNI, the Company were granted a worldwide, exclusive license on certain BNI intellectual property and the option to acquire the BNI IP within three years of the agreement. The BNI IP consists of generic Strontium Chloride SR89 (generic Metastron®) (“SR89”) and all of BNI’s intellectual property relating to it (“BNI IP”). SR89 is a radiopharmaceutical therapeutic for cancer bone pain therapy. The Company believes that it has fulfilled the obligations under the agreement to exercise an option to acquire the BNI IP and has notified BNI of such exercise, but BNI has not transferred the BNI IP to the Company. As a result, the Company has commenced litigation to, among other actions, obtain all of the BNI IP. The Company also seeks judgments against BNI and related parties for the misappropriation of funds, breach of contract, fraud and fraudulent inducement. In February 2019, such lawsuit was removed to the Federal court located in the Southern District of New York. On September 23, 2019, the Company entered into a settlement agreement with BNI and parties related to BNI. See Note 10 - Subsequent Events, below. Advisory Agreements The Company entered into customary consulting arrangements with various counterparties to provide consulting services, business development and investor relations services, pursuant to which the Company agreed to issue shares of common stock as services are received. Lease Agreement In December 2016, the Subsidiary entered into a lease agreement for its office space located in Cayman Islands for $30,000 per annum. The initial term of the agreement ends in December 2019 and can be renewed for another three years. Rent expense is classified within general and administrative expenses on a straight-line basis and included in the accompanying Condensed Consolidated Statements of Operations as follows: For the three months ended August 31, For the nine months ended August 31, 2019 2018 2019 2018 Rent expense $ 7,500 $ 7,500 $ 22,500 $ 23,000 License Agreement Mannin On October 29, 2015, the Company entered into a Patent and Technology License and Purchase Option Agreement (“Exclusive License”) with a vendor whereby the Company was granted a worldwide, exclusive, license on, and option to, acquire certain intellectual property (“Mannin IP”) which initially focused on developing a first-in-class eye drop treatment for glaucoma within the four-year term of the Exclusive License. On March 26, 2019, the Company entered into an amendment to the Patent and Technology License and Purchase Option Agreement that it initially entered into with Mannin Research Inc. on October 29, 2015 (the “Mannin Agreement”). Under such amendment, the term of the option granted under the Mannin Agreement was extended to October 29, 2021 in exchange for the Company issuing 100,000 shares to Mannin Research Inc. on April 9, 2019. During the nine months ended August 31, 2019 and 2018, the Company incurred approximately $1.9 million and $1.7 million, respectively, in research and development expenses to fund the costs of development of the eye drop treatment for glaucoma pursuant to the Exclusive License. Washington University On March 9, 2019, the Company entered into an Exclusive License Agreement with Washington University for license of a diagnostic marker for determining the severity of glaucoma using the expression levels of Growth Differentiation Factor 15. The agreement calls for the Company to pay an initial fee of approximately $88,000, pay annual maintenance fees ranging from $15,000 to $75,000, make additional payments upon the following milestones: · The first commercial sale of a companion diagnostic product; · Initiation of a clinical trial for a diagnostic product to support FDA PMA or 510(k) regulatory approval or the foreign equivalent; · PMA or 510(k) regulatory approval by the FDA or the foreign equivalent; and · The first commercial sale of a diagnostic product. In additional to the above payments, royalty payments based upon sales of a companion diagnostic product or diagnostic product are required.

Related Party Transactions

Related Party Transactions	9 Months Ended
	Aug. 31, 2019
Related Party Transactions
Related Party Transactions	Note 7 - Related Party Transactions The Company entered into consulting agreements with certain management personnel and stockholders for consulting and legal services. Consulting and legal expenses resulting from such agreements were included within general and administrative expenses in the accompanying Condensed Consolidated Statements of Operations as follows: For the three months ended August 31, For the nine months ended August 31, 2019 2018 2019 2018 Consulting and legal expenses $ 78,000 $ 60,000 $ 270,000 $ 180,000

Stockholders' Equity Deficit

Stockholders' Equity Deficit	9 Months Ended
	Aug. 31, 2019
Stockholders' Equity Deficit
Stockholders' Equity (Deficit)	Note 8 - Stockholders’ Equity Deficit As of August 31, 2019 and November 30, 2018, the Company is authorized to issue up to 250,000,000 shares of its $0.001 par value common stock and up to 100,000,000 shares of its $0.001 par value preferred stock. Issuance of shares for services During the nine months ended August 31, 2019, the Company issued an aggregate of 526,541 shares of the Company common stock to various vendors for advisory services, valued at approximately $886,000 based on the estimated fair market value of the stock on the date of grant and was recognized within general and administrative expenses in the accompanying Condensed Consolidated Statements of Operations. Issuance of shares to partially convert notes payable In August 2019, the Company issued an aggregate of 334,556 shares of the Company’s common stock to convert $293,726 of principal and accrued interest outstanding under the 2018 Debentures. Of the 334,556 shares, 146,863 shares were recognized as a conversion of debt at a conversion price of $2.00, while 187,693 shares were recognized as loss on induced conversion of convertible debt in the accompanying Condensed Consolidated Statements of Operations. See Note 5, above, for further discussion. Issuance of shares to defer monthly contingent payment of convertible note In August 2019, the Company issued an aggregate of 30,894 shares of the Company’s common stock, valued at approximately $31,000, to holders of the 2018 Debentures to defer a monthly contingent payment that became due. The estimated fair market value of the shares issued was recognized within interest expense in the accompanying Condensed Consolidated Statements of Operations.

Warrants and Options

Warrants and Options	9 Months Ended
	Aug. 31, 2019
Warrants and Options
Warrants and Options	Note 9 - Warrants and Options Summary of warrants The following represents a summary of all outstanding warrants to purchase the Company’s common stock, including warrants issued to vendors for services and warrants issued as part of the units sold in the private placements, at August 31, 2019 and the changes during the period then ended: Weighted Average Weighted Remaining Average Contractual Warrants Exercise Price Life (years) Intrinsic Value Outstanding at November 30, 2018 4,984,058 $ 3.48 3.51 $ 250,000 Issued — $ — $ — Expired — $ — $ — Outstanding at August 31, 2019 4,984,058 $ 3.48 2.76 $ — Exercisable at August 31, 2019 4,921,558 $ 3.49 2.75 $ — Fair value of all outstanding warrants issued to non-employees for services was calculated with the following key inputs: For the nine months ended August 31, 2018 Stock price $2.14 - $3.61 Term (years) 3.0 – 5.0 Volatility 123.00% - 128.49% Risk-free rate 2.47% - 2.78% Dividend yield 0.00% There were no warrants issued for the nine months ended August 31, 2019. Options issued for services The following represents a summary of all outstanding options to purchase the Company’s common stock at August 31, 2019 and the changes during the period then ended: Weighted Average Weighted Remaining Average Contractual Options Exercise Price Life (years) Intrinsic Value Outstanding at November 30, 2018 900,000 $ 3.68 3.99 $ — Issued 300,000 $ 1.53 4.75 $ — Outstanding at August 31, 2019 1,200,000 $ 3.15 3.62 $ — Exercisable at August 31, 2019 1,050,000 $ 3.38 3.46 $ — Fair value of options issued in the nine-month period ended August 31, 2018 was calculated with the following key inputs. No options were granted in the nine-month period ended August 31, 2019. For the nine months ended August 31, 2019 2018 Exercise price $1.53 $3.00 - $3.61 Expected term (years) 5.0 5.0 Volatility 98.75% 128.00% - 130.00% Risk-free rate 2.03% 2.52% - 2.71% Dividend yield 0.00% 0.00% Stock-based Compensation Stock-based compensation expense is classified within general and administrative expenses as a result of the shares, outstanding warrants and options issued to consultants and employees and included in the accompanying Condensed Consolidated Statements of Operations as follows: For the three months ended August 31, For the nine months ended August 31, 2019 2018 2019 2018 Stock-based compensation expense 183,000 946,000 463,000 1,500,000 As of August 31, 2019, the estimated unrecognized stock-based compensation associate with these agreements is approximately $136,000 and will be fully recognized over the next five months.

Subsequent events

Subsequent events	9 Months Ended
	Aug. 31, 2019
Subsequent events
Subsequent events	Note 10 – Subsequent events Research Collaboration On September 5, 2019, the Company entered into a research collaboration and master services agreement (the “Agreement”) with Chemveda Life Sciences India Private Limited (“Chemveda”), a contract research and manufacturing services company. The Company and Chemveda have been engaged in a collaborative joint research program since February 2017. Under the Agreement, the Company will continue the collaborative joint research program with Chemveda regarding the synthesis of Uttroside B, isolated from the leaves of Solanum nigrum, and any of its analogues for use in the clinical trials and treatment of Hepatocellular Carcinomas and any other targets and therapeutic areas (the “Program”). The term of the Agreement is for up to two years from execution. Under the Agreement and depending upon reaching certain milestones, the Company have agreed to pay Chemveda total compensation of up to $660,000, $360,000 of which will be payable in cash and $300,000 of which will be payable in stock. To date, the Company have paid Chemveda $210,000 in cash compensation under the Agreement and have made no compensation payments in stock. The Company have also agreed to pay royalties (capped at a total amount) to Chemveda based on net sales of any and all drug product(s) resulting from the collaboration, being developed by us. Subject to the terms of the Agreement, Chemveda shall have the first right of refusal and, if exercised, the exclusive right to manufacture any products developed as a result of the Program for precommercial and commercial production. Securities Purchase Agreements In September 2019, the Company executed securities purchase agreements with various investors to purchase units, each unit consisting of (i) one share of common stock and (ii) one and one half (1.5) warrants to purchase a share of common stock, at $0.86, which is 110% of the closing price of the Company’s common stock as listed on OTCQB on September 18, 2019, raising approximately $208,000 in cash. In October 2019, the Company issued 148,261 units (with each unit consisting of one share of common stock and 1.5 warrants to purchase a share of common stock) to the Company’s legal counsel in exchange for $91,922 of services provided. The Company’s Chief Legal Officer and a Director is the Managing Partner at the law firm where these services were provided. Amendment to 2018 Debentures On September 23, 2019, the Company and holder of the 2018 Debentures entered into an amendment agreement to the securities purchase agreement for the 2018 Debentures, pursuant to which, the conversion price of the 2018 Debentures was reduced to the lower of (i) $1.00, (ii) 93% of the average of the four lowest daily VWAPs during the 10 consecutive trading days immediately preceding the conversion date, provided that as long as we are not in default under the 2018 Debentures, the conversion price may never be less than $0.50, or (iii) a price agreed to by us and the investor. Additionally, the maturity date of the 2018 Debentures was extended to September 21, 2020. On September 23 and October 7, 2019, holders of the 2018 Debentures converted an aggregate of $531,992 of principal and accrued interest outstanding under the revised conversion terms and received an aggregate of 1,163,204 shares of the Company’s common stock. Had the holders converted $531,992 of principal and accrued interest under the previously existing conversion terms, the holders would have received 265,996 shares of the Company’s common stock. The additional 897,208 shares received upon conversion had an aggregate fair value of $589,223. Settlement Agreement As described in Note 6, above, the Company commenced litigation against BNI and parties related to BNI in the Supreme Court of New York, New York County o December 28, 2018. On September 23, 2019, the Company entered into a settlement agreement with BNI and parties related to BNI. Pursuant to the terms of the settlement agreement, the Company settled its dispute with BNI and all parties to the litigation dismissed their claims in exchange for entering into a Second Amendment to the License Agreement (entered into on September 23, 2019) pursuant to which: · BNI agreed to immediately transfer and/or assign to the Company all intellectual property, patents and products that is owned by BNI that is related to Strontium-Chloride 89; · The Company agreed to issue BNI 50,000 shares of its common stock upon the entry into the settlement agreement and 100,000 shares of its common stock upon the approval of the U.S. Food and Drug Administration (“FDA”) approval of BNI’s Prior Approval Supplements filing · The Company agreed to make a cash payment to BNI of $25,000 · The Company agreed to an on-going royalty payment of 3% on all gross profits derived by the Company from the sale of Strontium-Chloride 89 and MetastronTM; and · The Company agreed to assume fees and expenses related to (i) all outstanding CMO fees owed by BNI to IsoTherapeutics relating to Strontium-Chloride 89 (approximately $67,000), (ii) all outstanding fees owed by BNI to the FDA relating to Strontium-Chloride 89 (approximately $208,000) and (iii) related fees for the development and approval of Strontium-Chloride 89 following the date of the settlement agreement. The agreement to (i) make a cash payment of $25,000 to BNI, (ii) pay all outstanding CMO fees owed by BNI to IsoTherapeutics relating to Strontium-Chloride 89 (approximately $67,000), and (iii) issue to BNI 50,000 shares of the Company’s common stock are recognizable subsequent events with an aggregate fair value of approximately $125,000. All other portions of the settlement agreement are not recognizable subsequent events. As of August 31, 2019, the Company had recognized $125,000 in accrued expenses related to this matter. The agreement to assume fees owed by BNI to the FDA relating to Strontium-Chloride 89 is not a recognizable subsequent event as of August 31, 2019, as the fee is contingent as of the settlement agreement date and payment of the fee by the Company is not probable as of the settlement agreement date. Repricing of Existing Warrants On September 24, 2019, the Company reduced the exercise price of 950,000 options and warrants previously issued to Denis Corin for services as a director and for services as an officer to $1.25 per share and reduced the exercise price of 1,250,000 options and warrants previously issued to William Rosenstadt for services as a director and for services as an offer to $1.25 per share. On September 24, 2019, the Company reduced the exercise price of 360,000 options and warrants previously issued to Ari Jatwes for services as a consultant to $1.25 per share and reduced the exercise price of 50,000 warrants previously issued to Rick Panicucci for services as a director to $1.25 per share. Distribution Agreement On October 3, 2019, the Company entered into an exclusive distribution agreement for Strontium-89/Metastron™ with Jubilant Radiopharma for the U.S. market. Jubilant Radiopharma is an industry leading pharmaceutical company specializing in nuclear medicine focused on developing, manufacturing, commercializing and distributing high quality and sustainable diagnostic and therapeutic agents on a global scale. Issuance of Debentures On October 11, 2019, the Company entered into a securities purchase agreement with an accredited investor to place convertible debentures with a maturity date of eighteen months after the issuance thereof in the aggregate principal amount of up to $750,000 (the “Transaction”), provided that in case of an event of default, the debentures may become at the holder’s election immediately due and payable. The initial closing of the Transaction occurred on October 11, 2019 when the Company The holder may convert a debenture in its sole discretion at any time on or prior to maturity at the lower of $1.00 or 93% of the average of the four lowest daily VWAPs during the 10 consecutive trading days immediately preceding the conversion date, provided that as long as we are not in default under the debenture, the conversion price may never be less than $0.50. The holder may not convert any portion of a debenture if such conversion would result in the holder beneficially owning more than 4.99% of our then issued and common stock, provided that such limitation may be waived by the holder with 65 days’ notice. Any time after the six-month anniversary of the issuance of a debenture that the daily VWAP is less than $0.50 for a period of twenty consecutive trading days (the “Triggering Date”) and only for so long as such conditions exist after a Triggering Date as that term is defined in the Transaction documents, the Company shall make monthly payments beginning on the last calendar day of the month when the Triggering Date occurred. Each monthly payment shall be in an amount equal to the sum of (i) the principal amount outstanding as of the Triggering Date divided by the number of such monthly payments until maturity, (ii) a redemption premium of 20% in respect of such principal amount and (iii) accrued and unpaid interest hereunder as of each payment date. The Company may, no more than twice, obtain a thirty-day deferral of a monthly payment due as a result of a Triggering Date through the payment of a deferral fee in the amount equal to 10% of the total amount of such monthly payment. Each deferral payment may be paid by the issuance of such number of shares as is equal to the applicable deferral payment divided by a price per share equal to 93% of the average of the four lowest daily VWAPs during the 10 consecutive Trading Days immediately preceding the due date in respect of such monthly payment being deferred, provided that such shares issued will be immediately freely tradable shares in the hands of the holder.

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	9 Months Ended
	Aug. 31, 2019
Summary of Significant Accounting Policies
Recent accounting pronouncements	Recent accounting pronouncements On February 2016, the FASB issued ASU No. 2016‑02, Leases (Topic 842) . Under the new guidance, lessees will be required to recognize all leases (with the exception of short-term leases) on the balance sheet as a lease liability, which is a lessee’s obligation to make lease payments arising from a lease, measured on a discounted basis and a right-of-use asset, which is an asset that represents the lessee¹s right to use, or control the use of, a specified asset for the lease term. The guidance in ASU 2017‑11 is effective for the Company on December 1, 2019. Early adoption is permitted, and the guidance is to be applied using a full or modified retrospective approach. The Company is currently evaluating the impact of the new standard on its condensed consolidated financial statements. In July 2017, the FASB issued ASU 2017‑11, Earnings Per Share (Topic 260); Distinguishing Liabilities from Equity (Topic 480); Derivatives and Hedging (Topic 815): (Part I) Accounting for Certain Financial Instruments with Down Round Features, (Part II) Replacement of the Indefinite Deferral for Mandatorily Redeemable Financial Instruments of Certain Nonpublic Entities and Certain Mandatorily Redeemable Noncontrolling Interests with a Scope Exception. The ASU allows companies to exclude a down round feature when determining whether a financial instrument (or embedded conversion feature) is considered indexed to the entity’s own stock. As a result, financial instruments (or embedded conversion features) with down round features may no longer be required to be accounted classified as liabilities. A company will recognize the value of a down round feature only when it is triggered and the strike price has been adjusted downward. For equity-classified freestanding financial instruments, such as warrants, an entity will treat the value of the effect of the down round, when triggered, as a dividend and a reduction of income available to common shareholders in computing basic earnings per share. For convertible instruments with embedded conversion features containing down round provisions, entities will recognize the value of the down round as a beneficial conversion discount to be amortized to earnings. The guidance in ASU 2017‑11 is effective for the Company on December 1, 2019. Early adoption is permitted, and the guidance is to be applied using a full or modified retrospective approach. The Company is currently evaluating the impact of the new standard on its condensed consolidated financial statements.
Recent adopted pronouncements	Recent adopted pronouncements In May 2014, the FASB issued ASU 2014‑09, Revenue from Contracts with Customers (Topic 606), as modified by ASU 2015‑14, Revenue from Contracts with Customers (Topic 606): Deferral of the Effective Date , ASU 2016‑08, Revenue from Contracts with Customers (Topic 606): Principal versus Agent Considerations (Reporting Revenue Gross versus Net), ASU 2016‑10, Revenue from Contracts with Customers (Topic 606): Identifying Performance Obligations and Licensing , and ASU 2016‑12, Revenue from Contracts with Customers (Topic 606): Narrow-Scope Improvements and Practical Expedients . The revenue recognition principle in ASU 2014‑09 is that an entity should recognize revenue to depict the transfer of goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. In addition, new and enhanced disclosures will be required. Companies may adopt the new standard either using the full retrospective approach, a modified retrospective approach with practical expedients, or a cumulative effect upon adoption approach. The adoption of this standard on December 1, 2018 did not impact the Company’s condensed consolidated financial statements. In August 2016, the FASB issued ASU No. 2016‑15, Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments . This new standard clarifies certain aspects of the statement of cash flows, including the classification of debt prepayment or debt extinguishment costs or other debt instruments with coupon interest rates that are insignificant in relation to the effective interest rate of the borrowing, contingent consideration payments made after a business combination, proceeds from the settlement of insurance claims, proceeds from the settlement of corporate-owned life insurance policies, distributions received from equity method investees and beneficial interests in securitization transactions. This new standard also clarifies that an entity should determine each separately identifiable source of use within the cash receipts and payments on the basis of the nature of the underlying cash flows. In situations in which cash receipts and payments have aspects of more than one class of cash flows and cannot be separated by source or use, the appropriate classification should depend on the activity that is likely to be the predominant source or use of cash flows for the item. The adoption of this standard on December 1, 2018 did not impact the Company’s condensed consolidated financial statements. In June 2018, the FASB issued ASU 2018‑07, Compensation - Stock Compensation (Topic 718), Improvements to Nonemployee Share-Based Payment Accounting . This ASU is intended to simplify aspects of share-based compensation issued to non-employees by making the guidance consistent with the accounting for employee share-based compensation. The adoption of this standard on December 1, 2018 did not impact the Company’s condensed consolidated financial statements.

Loss per share (Tables)

Loss per share (Tables)	9 Months Ended
	Aug. 31, 2019
Loss per share
Loss per share	The table below summarizes potentially dilutive securities that were not considered in the computation of diluted net loss per share because they would be anti-dilutive. August 31, Potentially dilutive securities 2019 2018 Warrants 4,984,000 4,955,058 Convertible Notes 2,171,000 — Stock Options 1,200,000 900,000

Convertible Notes (Tables)

Convertible Notes (Tables)	9 Months Ended
	Aug. 31, 2019
Convertible Notes.
Long-term carrying value of convertible notes	August 31, 2019 November 30, 2018 Convertible Notes Payable, current: Principal value of 2019 Debenture $ 550,000 $ — Debt discount (65,000) — Carrying value of 2019 Debenture 485,000 — Total carrying value of convertible notes payable, current $ 485,000 $ — Convertible Notes Payable, long-term: Principal value of 2018 Debenture $ 3,800,000 $ 4,000,000.00 Fair value of bifurcated contingent put option 658,000 262,000 Debt discount (481,291) (1,388,728) Carrying value of 2018 Debenture 3,976,709 2,873,272 Total carrying value of convertible notes, long-term $ 3,976,709 $ 2,873,272
Fair value measurement inputs and valuation techniques	The Company estimated the fair value of the monthly payment provision by estimating the probability of the occurrence of a Triggering Date and applying the probability to the discounted maximum redemption premium for any given payment with the following key inputs: August 31, 2019 November 30, 2018 Stock price $0.91 $1.95 - $2.97 Terms (years) 0.50-0.66 1.2 - 1.4 Volatility 79.78% 72.1% - 76.5% Risk-free rate 1.89% - 2.10% 2.4% - 2.5% Dividend yield 0.00% 0.00% Discount rate 35.17% 35.17% In August 2019, the Company modified the conversion price for $293,726 of principal and accrued interest outstanding under the 2018 Debentures and holders immediately converted the amount into 334,556 shares of the Company’s common stock. Had the holders converted $293,726 of principal and
Schedule of interest expense	For the three months ended August 31, For the nine months ended August 31, 2019 2018 2019 2018 Interest expense based on the coupon interest rate of the outstanding debt $ 55,000 $ — $ 166,000 $ — Accretion of debt discount $ 389,000 $ — $ 907,000 $ — Costs incurred to defer monthly contingent payments of convertible notes $ 32,000 $ — $ 64,000 $ —

Commitments and Contingencies (

Commitments and Contingencies (Tables)	9 Months Ended
	Aug. 31, 2019
Commitments and Contingencies
Commitments and contingencies	Rent expense is classified within general and administrative expenses on a straight-line basis and included in the accompanying Condensed Consolidated Statements of Operations as follows: For the three months ended August 31, For the nine months ended August 31, 2019 2018 2019 2018 Rent expense $ 7,500 $ 7,500 $ 22,500 $ 23,000

Related Party Transactions (Tab

Related Party Transactions (Tables)	9 Months Ended
	Aug. 31, 2019
Related Party Transactions
Related party transactions	For the three months ended August 31, For the nine months ended August 31, 2019 2018 2019 2018 Consulting and legal expenses $ 78,000 $ 60,000 $ 270,000 $ 180,000

Warrants and Options (Tables)

Warrants and Options (Tables)	9 Months Ended
	Aug. 31, 2019
Schedule of stock-based compensation	For the three months ended August 31, For the nine months ended August 31, 2019 2018 2019 2018 Stock-based compensation expense 183,000 946,000 463,000 1,500,000
Warrants
Summary of all outstanding warrants and options to purchase of common stock	Weighted Average Weighted Remaining Average Contractual Warrants Exercise Price Life (years) Intrinsic Value Outstanding at November 30, 2018 4,984,058 $ 3.48 3.51 $ 250,000 Issued — $ — $ — Expired — $ — $ — Outstanding at August 31, 2019 4,984,058 $ 3.48 2.76 $ — Exercisable at August 31, 2019 4,921,558 $ 3.49 2.75 $ —
Schedule of fair value outstanding warrants and options issued to non-employees for services	For the nine months ended August 31, 2018 Stock price $2.14 - $3.61 Term (years) 3.0 – 5.0 Volatility 123.00% - 128.49% Risk-free rate 2.47% - 2.78% Dividend yield 0.00%
Options
Summary of all outstanding warrants and options to purchase of common stock	Weighted Average Weighted Remaining Average Contractual Options Exercise Price Life (years) Intrinsic Value Outstanding at November 30, 2018 900,000 $ 3.68 3.99 $ — Issued 300,000 $ 1.53 4.75 $ — Outstanding at August 31, 2019 1,200,000 $ 3.15 3.62 $ — Exercisable at August 31, 2019 1,050,000 $ 3.38 3.46 $ —
Schedule of fair value outstanding warrants and options issued to non-employees for services	For the nine months ended August 31, 2019 2018 Exercise price $1.53 $3.00 - $3.61 Expected term (years) 5.0 5.0 Volatility 98.75% 128.00% - 130.00% Risk-free rate 2.03% 2.52% - 2.71% Dividend yield 0.00% 0.00%

Warrants and Options (Tables)_2

Warrants and Options (Tables)	9 Months Ended
	Aug. 31, 2019
Basis of Presentation and Going Concern
Fair value measurement inputs and valuation techniques	The Company estimated the fair value of the monthly payment provision by estimating the probability of the occurrence of a Triggering Date and applying the probability to the discounted maximum redemption premium for any given payment with the following key inputs: August 31, 2019 November 30, 2018 Stock price $0.91 $1.95 - $2.97 Terms (years) 0.50-0.66 1.2 - 1.4 Volatility 79.78% 72.1% - 76.5% Risk-free rate 1.89% - 2.10% 2.4% - 2.5% Dividend yield 0.00% 0.00% Discount rate 35.17% 35.17% In August 2019, the Company modified the conversion price for $293,726 of principal and accrued interest outstanding under the 2018 Debentures and holders immediately converted the amount into 334,556 shares of the Company’s common stock. Had the holders converted $293,726 of principal and

Loss per share (Details)

Loss per share (Details) - shares	9 Months Ended
	Aug. 31, 2019	Aug. 31, 2018
Loss per share
Warrants	4,984,000	4,955,058
Convertible Notes	2,171,000
Stock Options	1,200,000	900,000

Convertible Notes (Details)

Convertible Notes (Details) - USD ($)	Aug. 31, 2019	Aug. 28, 2019	Nov. 30, 2018
Notes and Loans Payable, Current [Abstract]
Debt discount	$ (65,000)
Carrying value	485,000
Total carrying value of convertible notes payable, current	485,000
Notes and Loans, Noncurrent [Abstract]
Fair value of bifurcated contingent put option	658,000		$ 262,000
Debt discount	(481,291)		(1,388,728)
Total long-term carrying value of convertible notes	3,976,709		2,873,272
2019 Debenture [Member]
Notes and Loans Payable, Current [Abstract]
Principal value	550,000	$ 550,000
Carrying value	485,000
2018 Debenture [Member]
Notes and Loans, Noncurrent [Abstract]
Principal value	3,800,000		4,000,000
Carrying value	$ 3,976,709		$ 2,873,272

Convertible Notes - Fair Value

Convertible Notes - Fair Value Measurement Inputs (Details)	3 Months Ended	9 Months Ended
	Aug. 31, 2019USD ($)	Aug. 31, 2019USD ($)	Nov. 30, 2018USD ($)
Convertible Notes
Amortization of the debt discount	$ 389,000	$ 907,000
2018 Debenture [Member] | Stock price
Convertible Notes
Input	0.91	0.91
2018 Debenture [Member] | Stock price | Minimum
Convertible Notes
Input			1.95
2018 Debenture [Member] | Stock price | Maximum
Convertible Notes
Input			2.97
2018 Debenture [Member] | Terms (years) | Minimum
Convertible Notes
Input	0.50	0.50	1.2
2018 Debenture [Member] | Terms (years) | Maximum
Convertible Notes
Input	0.66	0.66	1.4
2018 Debenture [Member] | Volatility
Convertible Notes
Input	79.78	79.78	76.5
2018 Debenture [Member] | Volatility | Minimum
Convertible Notes
Input			72.1
2018 Debenture [Member] | Risk-free rate | Minimum
Convertible Notes
Input	1.89	1.89	2.4
2018 Debenture [Member] | Risk-free rate | Maximum
Convertible Notes
Input	2.1	2.1	2.5
2018 Debenture [Member] | Dividend yield
Convertible Notes
Input	0	0	0
2018 Debenture [Member] | Discount rate
Convertible Notes
Input			35.17

Convertible Notes - Interest Ex

Convertible Notes - Interest Expense (Details) - USD ($)	3 Months Ended		9 Months Ended
	Aug. 31, 2019	Aug. 31, 2018	Aug. 31, 2019	Nov. 30, 2018
Convertible Notes.
Interest Expense, Debt	$ 55,000		$ 166,000
Accretion of debt discount	$ 389,000		$ 907,000
Costs incurred to defer monthly contingent payments of convertible notes	$32,000	$-	$64,000	$-

Convertible Notes - Additional

Convertible Notes - Additional Information (Details) - USD ($)	Aug. 28, 2019	Aug. 31, 2019	Aug. 31, 2019	Aug. 31, 2018	Aug. 31, 2019	Aug. 31, 2018
Debt Instruments [Line Items]
Debt Instrument, Convertible, Conversion Price		$ 2	$ 2		$ 2
Debt Conversion, Description	The Company may pay such a redemption in cash and/or shares of its common stock. Any payment of such a redemption in shares of common stock shall be made at the lesser of $2.50 or 93% of the average of the four lowest VWAPs in the prior ten trading day, provided that no such conversion price shall be less than $2.00. Any payment of such a redemption in cash shall be at 120% of the amount being redeemed. Moreover, the Company has the right to defer up to two (2) separate redemptions for up to thirty (30) days each by providing written notice to the lender within three (3) trading days of its receipt of a redemption notice. In the event the Company elects to exercise its deferral right, the 2019 Debenture's outstanding balance shall automatically be increased by ten percent (10%) of the redemption amount to which such deferral relates.
Conversion of note		$ 293,726			$ 293,726
Debt Conversion, Converted Instrument, Shares Issued		334,556
Loss on induced conversion of debt			$ 197,078		197,078
2019 Debenture [Member]
Debt Instruments [Line Items]
Issue Of Debentures, Amount	$ 500,000
Short-term Debt	550,000	$ 550,000	$ 550,000		$ 550,000
Debt Issuance Costs, Gross	40,000
Legal Fees	$ 10,000
Debt Instrument, Interest Rate, Stated Percentage	10.00%
Debt Default, Interest rate (as a percent)	18.00%
Debt Instrument, Convertible, Conversion Price	$ 2.50
2019 Debenture [Member] | Maximum
Debt Instruments [Line Items]
Debt Instrument, Convertible, Conversion Price	$ 2
2019 Debenture [Member] | Within first six months
Debt Instruments [Line Items]
Debt Instrument, Redemption Price, Percentage	110.00%
2019 Debenture [Member] | Thereafter
Debt Instruments [Line Items]
Debt Instrument, Redemption Price, Percentage	125.00%
2019 Debenture [Member] | Thereafter | Maximum
Debt Instruments [Line Items]
Debt Instrument, Maximum Redemption Amount In Month	$ 150,000
2018 Debenture [Member]
Debt Instruments [Line Items]
Conversion of note		$ 293,726
Debt Conversion, Converted Instrument, Shares Issued		334,556
Issuance of common stock upon conversion of convertible notes , Shares		146,863
Stock Issued During Period, Shares, Inducement To Conversion of Convertible Securities		187,693
Loss on induced conversion of debt		$ 197,078

Commitments and Contingencies_2

Commitments and Contingencies (Details) - USD ($)	Apr. 09, 2019	Mar. 09, 2019	Dec. 31, 2016	Oct. 29, 2015	Aug. 31, 2019	Aug. 31, 2018	Aug. 31, 2019	Aug. 31, 2018	Nov. 30, 2018
Commitments and Contingencies
Research and development expenses					$ 786,600	$ 989,140	$ 2,672,715	$ 2,624,753
Rent expense					$ 7,500	$ 7,500	$ 22,500	$ 23,000
Legal agreement
Commitments and Contingencies
Term of option to acquire license (in years)							3 years
Lease agreement
Commitments and Contingencies
Lease cost per annum			$ 30,000
Renewal term (in years)			3 years
Mannin agreement
Commitments and Contingencies
License agreement (in years)				4 years
Shares issued in exchange for extension of option period	100,000
Research and development expenses							$ 1,900,000		$ 1,700,000
Washington university
Commitments and Contingencies
Initial fee		$ 88,000
Washington university | Minimum
Commitments and Contingencies
Annual maintenance fees		15,000
Washington university | Maximum
Commitments and Contingencies
Annual maintenance fees		$ 75,000

Convertible Notes (Details) - o

Convertible Notes (Details) - old - USD ($)	Aug. 31, 2019	Nov. 30, 2018
Basis of Presentation and Going Concern
Total long-term carrying value of convertible notes	$ 3,976,709	$ 2,873,272

Convertible Notes (Details Narr

Convertible Notes (Details Narrative) - USD ($)	1 Months Ended	3 Months Ended	9 Months Ended
	Aug. 31, 2019	Aug. 31, 2019	Aug. 31, 2019	Aug. 31, 2018
Debt Instrument [Line Items]
Conversion price	$ 2	$ 2	$ 2
Amortization of the debt discount		$ 389,000	$ 907,000
Shares issued for conversion	334,556
Convertible notes value	$ 293,726		293,726
Interest Expense, Debt		$ 55,000	$ 166,000

Related Party Transactions (Det

Related Party Transactions (Details) - USD ($)	3 Months Ended		9 Months Ended
	Aug. 31, 2019	Aug. 31, 2018	Aug. 31, 2019	Aug. 31, 2018
Related Party Transactions
Consulting and legal expenses	$ 78,000	$ 60,000	$ 270,000	$ 180,000

Commitments and Contingencies -

Commitments and Contingencies - Additional Information (Details) - USD ($)	1 Months Ended	3 Months Ended		9 Months Ended
	Dec. 31, 2016	Aug. 31, 2019	Aug. 31, 2018	Aug. 31, 2019	Aug. 31, 2018
Loss Contingencies [Line Items]
Research and development expenses		$ 786,600	$ 989,140	$ 2,672,715	$ 2,624,753
Legal agreement
Loss Contingencies [Line Items]
Term of option to acquire license (in years)				3 years
Lease agreement
Loss Contingencies [Line Items]
Lease cost per annum	$ 30,000
Renewal term (in years)	3 years

Stockholders' Equity Deficit (D

Stockholders' Equity Deficit (Details) - USD ($)	1 Months Ended	3 Months Ended		9 Months Ended
	Aug. 31, 2019	Aug. 31, 2019	Aug. 31, 2018	Aug. 31, 2019	Aug. 31, 2018	Nov. 30, 2018
Common stock, par value	$ 0.001	$ 0.001		$ 0.001		$ 0.001
Common stock, shares authorized	250,000,000	250,000,000		250,000,000		250,000,000
Preferred stock, par value	$ 0.001	$ 0.001		$ 0.001		$ 0.001
Preferred stock, shares authorized	100,000,000	100,000,000		100,000,000		100,000,000
Stock issued for services		$ 341,127	$ 1,181,450	$ 1,349,608	$ 1,953,317
Shares issued for conversion	334,556
Conversion of note	$ 293,726			$ 293,726
Shares recognized as conversion of debt	146,863
Conversion price	$ 2	$ 2		$ 2
Shares recognized loss on conversion of convertible debt	187,693
Stock issued during period shares contingent payment of convertible note	30,894
Stock issued during period value contingent payment of convertible note	$ 31,000
General and Administrative Expense
Stock issued for services (in shares)				526,541
Stock issued for services				$ 886,000

Warrants and Options - Summary

Warrants and Options - Summary of warrants (Details) - Warrants - $ / shares	9 Months Ended	12 Months Ended
	Aug. 31, 2019	Nov. 30, 2018
Warrants
Outstanding at November 30, 2018	4,984,058
Outstanding at August 31, 2019	4,984,058	4,984,058
Exercisable at August 31, 2019	4,921,558
Weighted Average Exercise Price
Outstanding at November 30, 2018	$ 3.48
Outstanding at August 31, 2019	3.48	$ 3.48
Exercisable at August 31, 2019	$ 3.49
Weighted Average Remaining Contractual Life (years)
Outstanding at November 30, 2018		3 years 6 months 4 days
Issued	0 years
Expired	0 years
Outstanding at August 31, 2019	2 years 9 months 4 days
Exercisable at August 31, 2019	2 years 9 months
Intrinsic Value
Outstanding at November 30, 2018		$ 250,000

Warrants and Options - Fair val

Warrants and Options - Fair value of outstanding warrants (Details) - Warrants	3 Months Ended
	Aug. 31, 2018$ / shares
Dividend yield	0.00%
Minimum
Stock price	$ 2.14
Term (years)	3 years
Volatility	123.00%
Risk-free rate	2.47%
Maximum
Stock price	$ 3.61
Term (years)	5 years
Volatility	128.49%
Risk-free rate	2.78%

Warrants and Options - Options

Warrants and Options - Options issued for services (Details) - Options - $ / shares	9 Months Ended	12 Months Ended
	Aug. 31, 2019	Nov. 30, 2018
Options
Outstanding at November 30, 2018	900,000
Issued	300,000
Outstanding at August 31, 2019	1,200,000	900,000
Exercisable at August 31, 2019	1,050,000
Weighted Average Exercise Price
Outstanding at November 30, 2018	$ 3.68
Issued	1.53
Outstanding at August 31, 2019	3.15	$ 3.68
Exercisable at August 31, 2019	$ 3.38
Weighted Average Remaining Contractual Life (years)
Outstanding at November 30, 2018		3 years 11 months 27 days
Issued	4 years 9 months
Outstanding at August 31, 2019	3 years 7 months 13 days
Exercisable at August 31, 2019	3 years 5 months 16 days

Warrants and Options - Fair v_2

Warrants and Options - Fair value of options (Details) - Options - $ / shares	9 Months Ended
	Aug. 31, 2019	Aug. 31, 2018
Exercise price	$ 1.53
Expected term (years)	5 years	5 years
Volatility	98.75%
Risk-free rate	2.03%
Dividend yield	0.00%	0.00%
Minimum
Exercise price		$ 3
Volatility		128.00%
Risk-free rate		2.52%
Maximum
Exercise price		$ 3.61
Volatility		130.00%
Risk-free rate		2.71%

Warrants and Options - Stock-ba

Warrants and Options - Stock-based Compensation (Details) - USD ($)	3 Months Ended		9 Months Ended
	Aug. 31, 2019	Aug. 31, 2018	Aug. 31, 2019	Aug. 31, 2018
Share-based Compensation			$ 1,349,608	$ 1,953,317
Unrecognized stock-based compensation	$ 136,000		$ 136,000
Unrecognized Compensation, Amortization Period			5 months
Consultants and employees | Warrants and options
Share-based Compensation	$ 183,000	$ 946,000	$ 463,000	$ 1,500,000

Subsequent events (Details)

Subsequent events (Details) - USD ($)

Oct. 07, 2019

Sep. 23, 2019

Sep. 05, 2019

Aug. 28, 2019

Oct. 31, 2019

Sep. 30, 2019

Aug. 31, 2019

Aug. 31, 2019

Aug. 31, 2018

Aug. 31, 2019

Aug. 31, 2018

Nov. 30, 2019

Subsequent Event [Line Items]

Debt Conversion, Description

The Company may pay such a redemption in cash and/or shares of its common stock. Any payment of such a redemption in shares of common stock shall be made at the lesser of $2.50 or 93% of the average of the four lowest VWAPs in the prior ten trading day, provided that no such conversion price shall be less than $2.00. Any payment of such a redemption in cash shall be at 120% of the amount being redeemed. Moreover, the Company has the right to defer up to two (2) separate redemptions for up to thirty (30) days each by providing written notice to the lender within three (3) trading days of its receipt of a redemption notice. In the event the Company elects to exercise its deferral right, the 2019 Debenture's outstanding balance shall automatically be increased by ten percent (10%) of the redemption amount to which such deferral relates.

Conversion of note

$ 293,726

$ 293,726

Debt Conversion, Converted Instrument, Shares Issued

334,556

Induced Conversion of Convertible Debt Expense

$ 197,078

$ 197,078

2018 Debenture [Member]

Subsequent Event [Line Items]

Conversion of note

$ 293,726

Debt Conversion, Converted Instrument, Shares Issued

334,556

Issuance of common stock upon conversion of convertible notes , Shares

146,863

Stock Issued During Period, Shares, Inducement To Conversion of Convertible Securities

187,693

Induced Conversion of Convertible Debt Expense

$ 197,078

Common Stock

Subsequent Event [Line Items]

Issuance of common stock upon conversion of convertible notes , Shares

146,863

146,863

Stock Issued During Period, Shares, Inducement To Conversion of Convertible Securities

187,693

187,693

Subsequent Event

Subsequent Event [Line Items]

Common Unit, Issued

148,261

Legal counsel in exchange services

$ 91,922

Subsequent Event | 2018 Debenture [Member]

Subsequent Event [Line Items]

Conversion of note

$ 531,992

$ 531,992

Debt Conversion, Converted Instrument, Shares Issued

1,163,204

1,163,204

Issuance of common stock upon conversion of convertible notes , Shares

265,996

265,996

Stock Issued During Period, Shares, Inducement To Conversion of Convertible Securities

897,208

897,208

Induced Conversion of Convertible Debt Expense

$ 589,223

$ 589,223

Subsequent Event | Common Stock

Subsequent Event [Line Items]

Common Unit, Issued

1

1

Subsequent Event | Warrants

Subsequent Event [Line Items]

Common Unit, Issued

1.5

1.5

Subsequent Event | Research Collaboration And Master Services Agreement [Member] | Chemveda Life Sciences India Private Limited [Member]

Subsequent Event [Line Items]

Value of stock to be issued

$ 300,000

Cash paid

210,000

Subsequent Event | Research Collaboration And Master Services Agreement [Member] | Chemveda Life Sciences India Private Limited [Member] | Maximum

Subsequent Event [Line Items]

Milestone payments

660,000

Cash payable

$ 360,000

Subsequent Event | Securities Purchase Agreements[Member] | Common Stock

Subsequent Event [Line Items]

Common Stock, Convertible, Conversion Price, Increase

$ 0.86

Common stock closing price (as a percent)

110.00%

Dividends, Common Stock, Cash

$ 208,000

Subsequent events - Settlement

Subsequent events - Settlement Agreement and Repricing of Exisiting Warrants (Details) - BNI and Parties Related To BNI [Member] - USD ($)	Sep. 23, 2019	Aug. 31, 2019
Subsequent Event [Line Items]
Accrued expenses		$ 125,000
Subsequent Event | Positive Outcome of Litigation [Member]
Subsequent Event [Line Items]
Number of shares awarded	100,000
Subsequent Event | Settled Litigation [Member] | Positive Outcome of Litigation [Member]
Subsequent Event [Line Items]
Number of shares awarded	50,000
Cash Payment Agreed	$ 25,000
Royalty Payment (as a percent)	3.00%
Total amount agreed to settle	$ 125,000
Subsequent Event | Settled Litigation [Member] | Positive Outcome of Litigation [Member] | Strontium-Chloride 89 [Member]
Subsequent Event [Line Items]
Outstanding fee settlement Owned by BNI to IsoTherapeutics	67,000
Outstanding fee settlement Owned by BNI to FDA	$ 208,000

Subsequent events - Repricing o

Subsequent events - Repricing of Existing Warrants (Details) - Subsequent Event - USD ($)	Sep. 24, 2019	Sep. 23, 2019
Ari Jatwes [Member] | Options And Warrants [Member]
Subsequent Event [Line Items]
Options and warrants issued	$ 360,000
Exercise price per share	$ 1.25
Rick Panicucci [Member] | Options And Warrants [Member]
Subsequent Event [Line Items]
Options and warrants issued	$ 50,000
Exercise price per share	$ 1.25
Share-based Payment Arrangement, Nonemployee [Member] | Director, Denis Corin [Member]
Subsequent Event [Line Items]
Exercise price per share		$ 1.25
Share-based Payment Arrangement, Nonemployee [Member] | Director, Denis Corin [Member] | Options And Warrants [Member]
Subsequent Event [Line Items]
Options and warrants issued		$ 950,000
Share-based Payment Arrangement, Nonemployee [Member] | Director, William Rosenstadt [Member] | Options And Warrants [Member]
Subsequent Event [Line Items]
Options and warrants issued		$ 1,250,000
Exercise price per share		$ 1.25

Subsequent events - Issuance of

Subsequent events - Issuance of Debentures (Details) - USD ($)	Oct. 11, 2019	Sep. 23, 2019	Aug. 28, 2019	Aug. 31, 2019	Aug. 31, 2019	Aug. 31, 2018
Subsequent Event [Line Items]
Conversion of note				$ 293,726	$ 293,726
Debt Conversion, Description			The Company may pay such a redemption in cash and/or shares of its common stock. Any payment of such a redemption in shares of common stock shall be made at the lesser of $2.50 or 93% of the average of the four lowest VWAPs in the prior ten trading day, provided that no such conversion price shall be less than $2.00. Any payment of such a redemption in cash shall be at 120% of the amount being redeemed. Moreover, the Company has the right to defer up to two (2) separate redemptions for up to thirty (30) days each by providing written notice to the lender within three (3) trading days of its receipt of a redemption notice. In the event the Company elects to exercise its deferral right, the 2019 Debenture's outstanding balance shall automatically be increased by ten percent (10%) of the redemption amount to which such deferral relates.
Conversion price				$ 2	$ 2
Subsequent Event | Issuance of Debentures [Member]
Subsequent Event [Line Items]
Value of debenture Issued	$ 500,000
Conversion of note	$ 250,000
Debt Default, Interest rate (as a percent)	5.50%
Additional Debt Instrument Debt Default Interest Rate	2.50%
Debt Conversion, Description	The holder may convert a debenture in its sole discretion at any time on or prior to maturity at the lower of $1.00 or 93% of the average of the four lowest daily VWAPs during the 10 consecutive trading days immediately preceding the conversion date, provided that as long as we are not in default under the debenture, the conversion price may never be less than $0.50. The holder may not convert any portion of a debenture if such conversion would result in the holder beneficially owning more than 4.99% of our then issued and common stock, provided that such limitation may be waived by the holder with 65 days' notice.	On September 23, 2019, the Company and holder of the 2018 Debentures entered into an amendment agreement to the securities purchase agreement for the 2018 Debentures, pursuant to which, the conversion price of the 2018 Debentures was reduced to the lower of (i) $1.00, (ii) 93% of the average of the four lowest daily VWAPs during the 10 consecutive trading days immediately preceding the conversion date, provided that as long as we are not in default under the 2018 Debentures, the conversion price may never be less than $0.50, or (iii) a price agreed to by us and the investor. Additionally, the maturity date of the 2018 Debentures was extended to September 21, 2020.
Redemption premium (as a percent)	20.00%
Deferral fee monthly payment (as a percent)	10.00%
Deferral payment divided (as a percent)	93.00%
Subsequent Event | Maximum | Issuance of Debentures [Member]
Subsequent Event [Line Items]
Principal value	$ 750,000
Conversion price	$ 0.50